MHRA Accepts Ultragenyx Application for Sanfilippo Gene Therapy
What happened
Ultragenyx announced that the UK Medicines and Healthcare products Regulatory Agency accepted its Marketing Authorisation Application for rebisufligene etisparvovec. This investigational gene therapy is intended for the treatment of mucopolysaccharidosis Type IIIA, also known as Sanfilippo syndrome Type A. The acceptance confirms that the application is sufficiently complete for the Agency to begin its formal scientific review, though final authorization is not guaranteed.
From finanznachrichten.de
Why it matters
The regulatory acceptance marks a significant milestone in the review process for the therapy. Ultragenyx must now proceed with reviews by the National Institute for Health and Care Excellence and the European Medicines Agency to advance its regulatory strategy.
From finanznachrichten.de
Who's involved
- National Institute for Health and Care ExcellenceWill conduct reviews on the therapy's cost and clinical benefit for UK market access.
- NasdaqThe American stock exchange where Ultragenyx is listed.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- BairdSpeculative
Baird might see its investment thesis affected by the positive regulatory milestone.
- ISISpeculative
ISI might see its investment thesis affected by the positive regulatory milestone.
The National Institute for Health and Care Excellence could accelerate the need for favorable cost-effectiveness appraisal.
Keep exploring
The entities involved
-
National Institute for Health and Care Excellence
non-departmental public body of the Department of Health in the United Kingdom
Nothing else this week.